A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
第3相
完了
NCT05138250
| 対象疾患 | COPD |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Sheffield Teaching Hospitals NHS Foundation Trust |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 31 名 |
|---|
| 介入（薬剤） | Mepolizumab 100 MG |
|---|
| 開始日 | 2022年5月8日 |
|---|
| 完了日 | 2025年5月8日 |
|---|
| 結果公開日 | 2026年5月7日 |
|---|
概要
The investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab. This is a licenced medication for asthma. Mepolizumab is a monoclonal antibody that acts through interleukin-5 (IL-5) antagonism to reduce blood eosinophil levels and is effective at reducing exacerbations in asthmatics. To determine whether mepolizumab may be an effective treatment in people with COPD and "asthmatic type" inflammation participants will have MRI scans before the treatment, after 12 weeks and after a year to see how the drug affects inflammation. The investigators will also compare our measurements with the number of exacerbations people get (measured by diaries), with measures of their quality of life (using a questionnaire), and with ordinary laboratory breathing tests. The investigators are especially interested to know if the reduction in inflammation early on after 12 weeks is associated with fewer exacerbations and better quality of life over the year.
Change in Percentage Ventilated Defect Percent (VDP)
Baseline to 12 weeks of treatment · % change in VDP
| Treatment Arm (All Participants, Not Randomised) | -0.14 ± 6.5 % change in VDP |
|---|
Change in Pulmonary Inflammation
From Baseline to 12 weeks of treatment · ratio
| Participants Completing Assessment 2 | -0.00009 ratio |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。